Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

CANCER:

Hodgkin Lymphoma

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related cancers:

‹

Lymphoma (1210)

Non-Hodgkin’s Lymphoma (1038)

Lymphoma (1210)

Non-Hodgkin’s Lymphoma (1038)

›

TNFRSF8 positive	Hodgkin Lymphoma	TNFRSF8 positive	Hodgkin Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	penpulimab Sensitive: A1 - Approval penpulimab Sensitive : A1	penpulimab Sensitive: A1 - Approval penpulimab Sensitive : A1
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	zimberelimab Sensitive: A1 - Approval zimberelimab Sensitive : A1	zimberelimab Sensitive: A1 - Approval zimberelimab Sensitive : A1
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	cyclophosphamide Sensitive: A1 - Approval cyclophosphamide Sensitive : A1	cyclophosphamide Sensitive: A1 - Approval cyclophosphamide Sensitive : A1
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	rituximab Sensitive: A2 - Guideline rituximab Sensitive : A2	rituximab Sensitive: A2 - Guideline rituximab Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	bortezomib Sensitive: A2 - Guideline bortezomib Sensitive : A2	bortezomib Sensitive: A2 - Guideline bortezomib Sensitive : A2